Trial Profile
Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID 2019 infections; Cytokine release syndrome; Severe acute respiratory syndrome
- Focus Therapeutic Use
- 22 Jun 2020 Planned End Date changed from 30 May 2022 to 2 Jun 2020.
- 22 Jun 2020 Planned primary completion date changed from 30 May 2022 to 2 Jun 2020.
- 22 Jun 2020 Planned initiation date changed from 30 May 2020 to 7 Apr 2020.